2024.Aug.07

Corporate

OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

OBI Pharma, a clinical-stage oncology company (4174.TWO), received the notification letter today from US FDA, stating that the request for Orphan Drug Designation of OBI-992 TROP2 ADC for the treatment of gastric cancer, including gastroesophageal junction cancer, has been approved.

HOMEWhat’s NewNewsOBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2024.Jul.30

OBI Pharma: An Exciting Launching Pad for Young Scientists

2024.Aug.22

The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs